ArticlePharmaceuticals (Basel, Switzerland)2023

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events.

Stephanie L Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.